http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 17:37:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25++Filed+by%3A+Pitts+Peter+Joe/26600556.html si-local-file:///var/storage/secattach/20260603/26600556.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25++Filed+by%3A+Pitts+Peter+Joe/26600556.html Wed, 03 Jun 2026 17:37:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25++Filed+by%3A+Pitts+Peter+Joe/26600556.html si-local-file:///var/storage/secattach/20260603/26600556.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25++Filed+by%3A+Pitts+Peter+Joe/26600556.html Wed, 03 Jun 2026 17:37:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++BRAINSTORM+CELL+THERAPEU+++++++++++++/26594888.html si-local-file:///var/storage/secattach/20260603/26594888.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++BRAINSTORM+CELL+THERAPEU+++++++++++++/26594888.html Wed, 03 Jun 2026 06:05:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++BRAINSTORM+CELL+THERAPEU+++++++++++++/26594888.html si-local-file:///var/storage/secattach/20260603/26594888.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++BRAINSTORM+CELL+THERAPEU+++++++++++++/26594888.html Wed, 03 Jun 2026 06:05:00 -0400 BCLI O.06500451 http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/Press+Releases/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html <div class="xn-content"> <p><i>Former FDA Associate Commissioner <person>Peter Pitts</person> and BrainStorm's <person>Chaim Lebovits</person> argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <span value="OTC-PINK:BCLI" idsrc="xmltag.org" >BrainStorm Cell Therapeutics Inc.</span> (OTCQB: BCLI) today announced the publication of an article examining how regulatory frameworks that govern ALS, rare diseases, and regenerative medicine can better keep pace with rapidly advancing science.</p> <div id="prni_dvprnejpga875left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpga875left" style="width: 400px; height: 134px;" title="BrainStorm Cell Therapeutics Logo" src="https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg" alt="BrainStorm Cell Therapeutics Logo" align="middle" /></div><p>As the ALS community marks http://www.streetinsider.com/PRNewswire/BrainStorm+Cell+Therapeutics+Announces+Publication+Calling+for+Updated+FDA+Approaches+to+ALS%2C+Rare+Diseases+and+Regenerative+Medicine/26588584.html Tue, 02 Jun 2026 09:00:00 -0400 A.50210626 BCLI O.06500451 O.23744242 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Lebovits+Chaim/26576347.html si-local-file:///var/storage/secattach/20260529/26576347.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Lebovits+Chaim/26576347.html Fri, 29 May 2026 17:03:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Lebovits+Chaim/26576347.html si-local-file:///var/storage/secattach/20260529/26576347.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Lebovits+Chaim/26576347.html Fri, 29 May 2026 17:03:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Patlis+Alla/26576331.html si-local-file:///var/storage/secattach/20260529/26576331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Patlis+Alla/26576331.html Fri, 29 May 2026 17:02:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Patlis+Alla/26576331.html si-local-file:///var/storage/secattach/20260529/26576331.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Patlis+Alla/26576331.html Fri, 29 May 2026 17:02:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Yablonka+Uri/26576340.html si-local-file:///var/storage/secattach/20260529/26576340.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Yablonka+Uri/26576340.html Fri, 29 May 2026 17:02:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Yablonka+Uri/26576340.html si-local-file:///var/storage/secattach/20260529/26576340.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+Yablonka+Uri/26576340.html Fri, 29 May 2026 17:02:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+ARBEL+IRIT/26576286.html si-local-file:///var/storage/secattach/20260529/26576286.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+ARBEL+IRIT/26576286.html Fri, 29 May 2026 17:01:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+ARBEL+IRIT/26576286.html si-local-file:///var/storage/secattach/20260529/26576286.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+ARBEL+IRIT/26576286.html Fri, 29 May 2026 17:01:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+FRENKEL+JACOB+A/26576305.html si-local-file:///var/storage/secattach/20260529/26576305.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+FRENKEL+JACOB+A/26576305.html Fri, 29 May 2026 17:01:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+FRENKEL+JACOB+A/26576305.html si-local-file:///var/storage/secattach/20260529/26576305.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BRAINSTORM+CELL+THERAPEU++For%3A+Feb+26++Filed+by%3A+FRENKEL+JACOB+A/26576305.html Fri, 29 May 2026 17:01:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25/26567200.html si-local-file:///var/storage/secattach/20260528/26567200.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25/26567200.html Thu, 28 May 2026 16:06:00 -0400 BCLI O.06500451 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25/26567200.html si-local-file:///var/storage/secattach/20260528/26567200.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BRAINSTORM+CELL+THERAPEU++For%3A+May+25/26567200.html Thu, 28 May 2026 16:06:00 -0400 BCLI O.06500451 http://www.streetinsider.com/Board+Changes/BrainStorm+Cell+Therapeutics+adds+former+FDA+associate+commissioner+to+board/26561222.html <p>BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) appointed Peter J. Pitts to its board of directors, effective immediately, the company announced.</p> <p>Pitts previously served as associate commissioner at the U.S. Food and Drug Administration and as a member of the U.S. Senior Executive Service. He currently serves as president and co-founder of the Center for Medicine in the Public Interest.</p> <p>The appointment comes as BrainStorm prepares to initiate its Phase 3b trial evaluating NurOwn for amyotrophic lateral sclerosis (ALS) under an FDA Special Protocol Assessment. The company stated this represents the first Special Protocol Assessment granted for an ALS therapeutic candidate.</p> <p>"BrainStorm is conducting http://www.streetinsider.com/Board+Changes/BrainStorm+Cell+Therapeutics+adds+former+FDA+associate+commissioner+to+board/26561222.html Thu, 28 May 2026 07:45:18 -0400 A.01908724 A.06822034 A.31066700 A.60012012 BCLI O.06500451 O.20026344 O.20847516 O.20988509 O.22422661